Mist Therapeutics

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. The company's lead product, CARDAMYST (etripamil) nasal spray, is an FDA-approved, self-administered calcium channel blocker designed for the rapid conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. Milestone is also advancing etripamil for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to shift acute cardiac care from the hospital to the home setting. By providing patients with on-demand, portable therapies, the company seeks to improve patient autonomy and reduce the burden on emergency medical services.